Dott.ssa Federica Tadiotto

Specialista in Diabetologia e Malattie endocrine

DAL 2000 AL 2014
Dirigente Medico Ulss 17 UOC Medicina e UOSD Diabetologia

Dal 20014 ad oggi Dirigente Medico ULSS 6 Euganea presso Unità Malattie Endocrino Metaboliche Ospedali Riuniti Padova Sud

Referente Patologia vascolare ed Ecografia capo collo UOSD Malattie Endocrino Metaboliche Ulss 6

Laurea in Medicina e Chirurgia nel 1995 presso Università di Padova

Specializzazione in Endocrinologia e Malattie del Metabolismo nel 2000 con votazione 70/70 lode
presso l’Università di Padova

Diploma in Diagnostica Vascolare Ultrasonografica nel 1999 GIUV

Alta Specializzazione in Diagnostica Vascolare con particolare attenzione alle patologie vascolari nei pazienti diabetici

– 2014 Clinical Therapeutics- Volume 1, Number 1:”Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patientes treated with Liraglutide in a real wordld setting in Italy
– Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy Cli Ther 2015 Mar 1;37(3):574-84.
o doi: 10.1016/j.clinthera.2014.11.015. Epub 2015 Jan 24.
– “Effectiveness of dulaglutide vs liraglutide and exenatide one-weekly.A real-word study and meta –analisys of observational studies”
– The journal of Clinical Endovrinology and Metabolism jc 2019-40459
– Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study “Diabetes Obes Metab. 2019;21:2542–2552
– Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care
– Diabetes Research and Clinical Practice Available February2021
– Effectiveness of dulaglutide in the real-world and in special populations of type 2 diabetic patients
– J.clinical Metab , 2020
– Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists.
– A multicenter longitudinal study –Nutr Metab Cardiovasc-Dis 2021, nov
– Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy- Acta Diabetol 2020

Relatore e Responsabile scientifico di numerosi congressi in ambito Diabetologico ,Endocrinologico e sulla patologia Vascolare

Partecipazone a numerosi corsi di ecografia vascolare , capo collo e internistica